Last $3.18 USD
Change Today -0.05 / -1.55%
Volume 321.0K
CYTR On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 11:16 AM 04/21/14 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$3.26
Previous Close
$3.23
Day High
$3.27
Day Low
$3.15
52 Week High
01/30/14 - $8.35
52 Week Low
06/24/13 - $1.95
Market Cap
176.7M
Average Volume 10 Days
1.7M
EPS TTM
$-1.24
Shares Outstanding
55.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate includes aldoxorubicin that has completed Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi’s sarcoma. It also develops aldoxorubicin, which is in Phase Ib/II clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and is in Phase IIb pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition, the company has evaluated a drug candidate bafetinib, in the ENABLE Phase II clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

cytrx corp (CYTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $500.0K
Senior Vice President of Drug Development
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

cytrx corp (CYTR) Key Developments

Law Offices of Howard G. Smith Files Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith announced that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all purchasers of the securities of CytRx Corporation between November 20, 2013 and March 13, 2014, inclusive.

CytRx to Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results at the 2014 AACR Annual Meeting

CytRx Corporation announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA. CytRx announced data from the trial, which demonstrated that aldoxorubicin significantly increased survival almost 2 1/2 fold compared to doxorubicin treatment in an in vivo xenograft tumor model employing growth of human glioblastoma multiforme (GBM) tumors in mouse brains. Aldoxorubicin, but not doxorubicin, also demonstrated preferential accumulation and prolonged retention in the tumor tissue. These data, combined with aldoxorubicin's favorable safety profile, support the current evaluation of aldoxorubicin as a treatment for patients with GBM tumors. CytRx is currently conducting a Phase 2 clinical trial evaluating aldoxorubicin in patients with late-stage GBM. In this trial, aldoxorubicin demonstrated 80-100% superiority over doxorubicin in progression-free survival (PFS). Median PFS, 6-month PFS and overall response rates all significantly favored aldoxorubicin treatment over doxorubicin. Aldoxorubicin is also being studied in a Phase 2 clinical trial in HIV-related Kaposi's sarcoma. CytRx also has initiated, under a special protocol assessment, a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas.

CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma

CytRx Corporation announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3.5 to 4 times) without several of the major treatment-limiting toxicities seen with administration of doxorubicin alone. This multicenter, randomized, open-label Phase 3 clinical trial is designed to enroll approximately 400 patients with metastatic, locally advanced or unresectable soft tissue sarcomas who have either not responded to, or have progressed following treatment with, one or more systemic regimens of non-adjuvant chemotherapies. Trial patients will be randomized 1:1 to be treated with aldoxorubicin or the investigator's choice of an approved chemotherapeutic regimen, including doxorubicin, ifosfamide dacarbazine, pazopanib (Votrient(R)), or gemcitabine plus docetaxel, with up to three comparator regimens to be selected by the investigator at each clinical site. The primary endpoint of the study is progression-free survival (PFS), and secondary endpoints include overall survival, response rates and safety. In January 2014, the Company announced it has received approval from the FDA to amend the Phase 3 protocol to continue dosing patients with aldoxorubicin until disease progression (defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion), which creates the potential for substantially improved Phase 3 efficacy results. The company expects to complete trial enrollment in 2015. A phase 1b/2 study, partial responses were observed in 5 of 13 patients with metastatic soft tissue sarcomas who had progressed following initial chemotherapy. Eight of 13 patients showed evidence of tumor shrinkage; 5 of the 8 patients had received prior doxorubicin chemotherapy and had not demonstrated tumor reduction. Updated analysis of median progression-free survival in patients has reached over 17 months without subsequent treatments. The clinical trial will be conducted at approximately 100 clinical sites in the U.S., Europe, Canada, Latin America, Asia Pacific and Australia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $3.18 USD -0.05

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 433.7x
Price/Book 12.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 469.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.